Cocrystal Pharma
COCPCocrystal Pharma is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule antiviral therapeutics for serious and chronic RNA viral diseases.
Table of contents
Earnings
Next report
Aug 13, 2026 (In 2 weeks)Competitors
By market cap
Profile
Cocrystal Pharma is a clinical-stage biotechnology company focused on the discovery and development of novel small molecule antiviral therapeutics for serious and chronic RNA viral diseases. The company utilizes a proprietary structure-based drug discovery platform, guided by Nobel Prize-winning expertise, to design direct-acting antivirals that target highly conserved regions of viral enzymes. Their core value proposition lies in creating broad-spectrum treatments with high barriers to drug resistance for infections including influenza, norovirus, and coronaviruses.
A clinical-stage innovator using a proprietary structure-based platform to target highly conserved viral regions, aiming for best-in-class broad-spectrum efficacy.
Questions, answered.
- What is Cocrystal Pharma's market cap?
- Cocrystal Pharma (COCP) has a market capitalization of $12.7M and trades on NASDAQ.
- Who are Cocrystal Pharma's competitors?
- Cocrystal Pharma's key competitors include Gilead Sciences, Inc., Pfizer Inc., Moderna, Inc., and others. These companies compete in similar markets and product categories.
- Who does Cocrystal Pharma partner with?
- Cocrystal Pharma's notable partners include Merck & Co., Emory University School of Medicine.
- Where is Cocrystal Pharma headquartered?
- Cocrystal Pharma is headquartered in United States of America and employs approximately 12 people. It has been publicly traded since 2008.